RxDoctor Payments Data

Homa Timlin, MD

Rheumatology · Baltimore, MDNPI 1235460866

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $782 of the $889 with a category attached, or 88.0%. 7 manufacturers reported payments, led by Amgen at 22.9% of the total. That places this record below the midpoint for rheumatology clinicians in MD, where the typical reported total is $2,316.

$889in general payments, 2019–2025

Across 9 payments — averaging $98.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$204
  • UCB, Inc.$139
  • Johnson & Johnson$130
  • AbbVie$125
  • Genentech, Inc.$107
  • Sobi, Inc$94
  • plus $90 from 1 others
$154,612in research payments, 2019–2025

Across 10 payments — averaging $15,461 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$155K

What the payments were for

  • Food & beverage$78288%
  • Education$10712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$889 in reported general payments places this provider in the 30th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$47,194
Medicare patients
72
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LupkynisVoclosporin16$190,053
BenlystaBelimumab25$148,343
Hydroxychloroquine Sulfate165$7,399
Mycophenolate Mofetil32$4,015
Leflunomide11$1,384
Famotidine24$540
Prednisone25$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aurinia Pharma U.S., Inc.Lupkynis$90$190,05316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →